
Diabetic retinopathy is a complication of diabetes, caused by high blood sugar levels damaging the back of the eye (retina).
Diabetes is a complex metabolic disorder that impairs the body’s ability to produce or use insulin effectively to regulate blood sugar levels. Over time, elevated blood sugar levels can cause damage throughout the body, leading to complications that affect overall health and wellbeing. Diabetes contributes to the development of heart disease, stroke, kidney disease, eye problems, nerve impairment, and issues affecting the extremities.
The term “diabetic eye disease” refers to a group of conditions that can threaten the eyesight of individuals with diabetes, including diabetic retinopathy, diabetic macular edema (DME), cataracts, and glaucoma.
Diabetic retinopathy is the most common cause of vision loss among individuals with diabetes. It occurs as a result of damage to the tiny blood vessels in the retina at the back of the eye. In its early stages, symptoms may not be noticeable, but as the condition progresses, it can lead to severe vision problems and even blindness. Approximately half of those with diabetic retinopathy may also develop diabetic macular edema, which affects the central retina responsible for reading, driving, and recognizing faces.
Background diabetic retinopathy, also known as non-proliferative diabetic retinopathy, is an early stage of the disease and provides visible signs of small blood vessel damage. Because the tiny aneurysms and hemorrhages that define this stage may not cause immediate vision changes, many individuals remain unaware of the condition. However, once detected, it signals an increased risk for more advanced disease and potential vision loss.
For individuals with diabetes, regular dilated eye examinations are essential for early detection and prevention of vision loss. In addition to scheduling comprehensive eye exams and maintaining proper blood sugar control, it is important to monitor any changes in vision. Contact your eye care provider promptly if you notice sudden changes, such as blurry, spotty, or hazy vision.
Diabetic retinopathy is a complication of diabetes that damages the small blood vessels of the retina, the light-sensitive layer at the back of the eye. Chronic high blood sugar weakens and deforms these vessels, causing leakage, swelling, or closure that interferes with normal retinal function. Over time this vascular damage can reduce visual acuity and, if untreated, can lead to severe vision loss or blindness.
Early stages of the disease often produce no noticeable symptoms, which is why clinical screening is essential for people with diabetes. As the condition advances, patients may experience blurred vision, floaters, dark areas in the field of vision, or sudden vision loss. Timely diagnosis and intervention can slow or halt progression and preserve functional vision.
Diabetic retinopathy is caused primarily by prolonged exposure to elevated blood glucose levels that damage retinal microvasculature. Additional factors that increase risk include the duration of diabetes, poor blood sugar control, high blood pressure, high cholesterol, smoking, and kidney disease. Type 1 and type 2 diabetes both carry risk, and the likelihood of retinopathy increases the longer a person has diabetes.
People who develop diabetes at a younger age or who have other vascular conditions face a higher probability of vision-threatening retinopathy. Pregnancy can also accelerate retinopathy progression, so pregnant patients with diabetes should receive close ophthalmic monitoring. Regular coordination between eye care and primary diabetes teams is important for risk reduction and early detection.
Diabetic retinopathy is typically described in stages that reflect disease severity and the presence of new vessel formation. The earliest stage, nonproliferative diabetic retinopathy, is marked by microaneurysms, dot hemorrhages and retinal swelling; many patients have no symptoms at this stage. As the disease advances to proliferative diabetic retinopathy, abnormal new blood vessels grow on the retinal surface and into the vitreous, raising the risk of bleeding and tractional retinal detachment.
Diabetic macular edema, which can occur at any stage, affects the central retina and is a leading cause of vision impairment in diabetic patients. Clinicians use retinal examination, optical coherence tomography (OCT) and widefield imaging to classify stage and guide treatment. Staging helps determine surveillance intervals and whether urgent intervention is needed to protect vision.
Identifying the stage early enables targeted care designed to minimize sight-threatening complications and preserve quality of life. Interdisciplinary management with endocrinology and primary care supports systemic risk factor control that complements ophthalmic treatment. Each patient’s stage informs a personalized plan for monitoring and therapy.
Any sudden change in vision warrants prompt evaluation, including new floaters, flashes of light, a shadow or curtain over part of the visual field, or abrupt blurring of central vision. Intermittent or progressive blurring, difficulty reading, and distortion of straight lines are also signs that should not be ignored. These symptoms can indicate active bleeding, macular swelling, or retinal detachment—conditions that may require urgent treatment.
Because early diabetic retinopathy can be asymptomatic, routine annual eye exams are recommended even without symptoms. Patients should contact their eye care provider right away if they notice any sudden visual changes or if routine screening reveals progression. Rapid assessment increases the chance of preserving vision through timely medical or surgical intervention.
Diagnosis begins with a comprehensive dilated eye exam to allow detailed visualization of the retina and optic nerve. Ophthalmologists use slit-lamp biomicroscopy, indirect ophthalmoscopy, fundus photography and optical coherence tomography (OCT) to identify vascular changes, macular edema, and areas of nonperfusion. Fluorescein angiography may be used when additional detail about blood flow and leakage patterns is needed to guide treatment.
Findings are documented and staged so the care team can recommend an appropriate follow-up and treatment plan. Imaging technologies provide objective measurements that allow clinicians to monitor disease activity and response to therapy over time. Coordination with the patient’s diabetes care team helps address systemic factors that influence ocular outcomes.
Treatment depends on stage and severity and may include intravitreal injections, focal or panretinal laser therapy, and vitrectomy surgery when indicated. Anti-VEGF injections are commonly used to reduce macular edema and regress abnormal blood vessels, while laser photocoagulation can seal leaky vessels and decrease the risk of severe vision loss in proliferative disease. Vitrectomy is reserved for nonclearing vitreous hemorrhage or tractional retinal detachment and aims to restore a clearer visual axis and relieve traction.
Clinical decisions are individualized based on imaging findings, visual acuity, extent of retinal ischemia, and overall health status. Many patients require ongoing treatments and monitoring to maintain visual stability. Close follow-up allows clinicians to adjust therapy promptly in response to changes and to combine modalities when a single approach is insufficient.
Systemic disease control remains a cornerstone of treatment success, so ophthalmic interventions are most effective when paired with tight glycemic, blood pressure and lipid management. Patient education about the goals and expected course of each therapy helps set realistic expectations and improves adherence to follow-up care. Collaborative care between the eye specialist and the patient’s primary diabetes providers optimizes long-term outcomes.
Diabetic macular edema (DME) occurs when fluid accumulates in the macula, the central portion of the retina responsible for sharp, detailed vision. DME can develop at any stage of diabetic retinopathy and is a leading cause of vision impairment in people with diabetes. Optical coherence tomography (OCT) is the primary imaging tool to detect and quantify macular swelling and to monitor response to therapy.
Treatment for DME commonly includes intravitreal injections of anti-VEGF medications to reduce vascular leakage and swelling, and focal laser therapy in select cases to stabilize localized areas of leakage. Response to treatment varies, so clinicians typically reassess visual acuity and OCT measurements after initial therapy and tailor subsequent care accordingly. Optimizing systemic control of blood sugar, blood pressure and cholesterol also helps reduce the risk and severity of DME.
Effective prevention and slowing of progression rely on tight control of blood glucose, blood pressure and lipid levels, which reduce stress on retinal blood vessels. Smoking cessation, regular physical activity, and adherence to diabetes care plans contribute to better systemic control and lower the risk of eye complications. Patients should maintain routine, dilated eye exams so early changes can be detected and treated before they threaten vision.
Education and coordination with the primary diabetes team are essential components of prevention, since ophthalmic treatments are most beneficial when systemic risks are managed. Pregnant patients and those with rapidly changing health should receive closer ophthalmic surveillance because disease can accelerate under those conditions. Early intervention based on scheduled screening and symptom awareness offers the best chance to preserve long-term vision.
Documenting retinal status and following recommended screening intervals enable timely escalation to medical or surgical therapies when needed. Empowering patients with clear information about symptoms and the importance of follow-up helps ensure adherence and improves outcomes. Preventive measures are a shared responsibility between the patient and their multidisciplinary care team.
Screening frequency depends on the type of diabetes, disease duration and previous retinal findings, but most adults with diabetes should have an annual dilated eye exam as a baseline. Patients with no retinopathy and good systemic control may be monitored at longer intervals when recommended by their ophthalmologist, while those with any level of retinopathy typically require more frequent follow-up. Individuals with rapidly changing vision or recent pregnancy should be evaluated sooner.
Ophthalmic imaging such as OCT and fundus photography helps determine appropriate surveillance intervals by documenting stability or progression. The care team will provide a personalized schedule based on retinal health, visual function and systemic risk factors. Consistent adherence to the recommended exam plan is one of the most effective ways to prevent vision loss from diabetic eye disease.
Referral to a cornea or vitreoretinal specialist is indicated when diabetic retinopathy or its complications require specialized surgical management, such as nonclearing vitreous hemorrhage, tractional retinal detachment, or significant macular pathology unresponsive to medical therapy. A cornea specialist may also be involved when anterior segment issues complicate posterior segment surgery or when complex ocular surface disease coexists. Timely referral ensures patients receive the appropriate surgical expertise for sight-threatening conditions.
At New York Cornea Consultants & Aesthetics, the team evaluates surgical need based on detailed imaging, visual function and the patient's overall medical status, coordinating care with the referring physician to plan perioperative management. Surgical decisions are made only after conservative options have been considered and when the expected benefit for vision outweighs the inherent risks. Clear communication about goals, potential outcomes and follow-up care helps patients make informed choices about advanced interventions.
